Disease details

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

1 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2012-005394-31-GB (EUCTR)	01/04/2014	05/09/2014	MS-SMART: A Trial of Efficacy (usefulness) of 3 Neuroprotective Drugs in SPMS	MS-SMART: A Multi-Arm Phase IIb Randomised, Double Blind Placebo-Controlled Clinical Trial Comparing The Efficacy of Three Neuroprotective Drugs in Secondary Progressive Multiple Sclerosis - MS-SMART: Multiple Sclerosis Secondary Progressive Multi-Arm Randomisation Trial	Mutliple Sclerosis (Secondary Progressive);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Rilutek Product Name: Rilutek INN or Proposed INN: Riluzole Trade Name: Amiloride Product Name: Amiloride INN or Proposed INN: Amiloride Trade Name: Fluoxetine Product Name: Fluoxetine INN or Proposed INN: Fluoxetine hydrochloride	UCL	NULL	Not Recruiting			Female: yes Male: yes	440	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	United Kingdom